Richard Hans Gomer

US Patent:

7763256, Jul 27, 2010

Filed:

Sep 27, 2006

Appl. No.:

11/535636

Inventors:

Richard Gomer - Houston TX, US
Darrell Pilling - Pearland TX, US

Assignee:

William Marsh Rice University - Houston TX

International Classification:

A61K 38/00
C07K 7/00
C07K 14/00

US Classification:

4241981, 514 2, 530350

Abstract:

The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate differentiation into fibrocytes. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.

US Patent:

7935682, May 3, 2011

Filed:

Jun 22, 2005

Appl. No.:

11/158723

Inventors:

Richard Gomer - Houston TX, US
Darrell Pilling - Pearland TX, US

Assignee:

William Marsh Rice University - Houston TX

International Classification:

A61K 31/715
A61K 31/729
A61K 38/18
A61K 45/00
A61K 9/14
A61K 9/16

US Classification:

514 54, 424 852, 424484, 424488, 424491

Abstract:

The present invention relates to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-4 and IL-3 to enhance the differentiation of monocytes into fibrocytes. Methods and compositions for binding SAP, decreasing SAP levels and suppressing SAP activity are provided. Methods of using, inter alia, CPHPC, the 4,6-pyruvate acetyl of beta-D-galactopyranose, ethanolamines, high EEO agarose, IL-4, and IL-13, and anti-SAP antibodies and fragments thereof to increase monocyte differentiation into fibrocytes are provided. These methods are useful in a variety of applications, including wound healing. Wound dressings are also provided. Finally, the invention may include assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects.

US Patent:

8012472, Sep 6, 2011

Filed:

Sep 27, 2006

Appl. No.:

11/535649

Inventors:

Richard Gomer - Houston TX, US
Darrell Pilling - Pearland TX, US

Assignee:

William Marsh Rice University - Houston TX

International Classification:

A61K 39/395

US Classification:

4241301, 514826, 514885

Abstract:

The present invention relates to the ability of anti-FcγR antibodies to suppress fibrocytes. Methods and compositions for suppressing fibrocytes are provided. These methods are useful in a variety of applications including treatment and prevention of conditions resulting from fibrosis in the liver, kidney, lung, heart and pericardium, eye, skin, mouth, pancreas, gastrointestinal tract, brain, breast, bone marrow, bone, genitourinary system, a tumor, or a wound.

US Patent:

8057802, Nov 15, 2011

Filed:

Dec 24, 2008

Appl. No.:

12/343606

Inventors:

Richard Gomer - Houston TX, US
Darrell Pilling - Pearland TX, US

Assignee:

William Marsh Rice University - Houston TX

International Classification:

A61K 38/00
C07K 7/00
C07K 14/00

US Classification:

4241981, 514 2, 530350

Abstract:

The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate differentiation into fibrocytes. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.

US Patent:

8187599, May 29, 2012

Filed:

Sep 2, 2011

Appl. No.:

13/224959

Inventors:

Richard Gomer - Houston TX, US
Darrell Pilling - Pearland TX, US

Assignee:

William Marsh Rice University - Houston TX

International Classification:

A61K 39/395

US Classification:

4241301, 514885

Abstract:

The present invention relates to the ability of anti-FcγR antibodies to suppress fibrocytes. Methods and compositions for suppressing fibrocytes are provided. These methods are useful in a variety of applications including treatment and prevention of conditions resulting from fibrosis in the liver, kidney, lung, heart and pericardium, eye, skin, mouth, pancreas, gastrointestinal tract, brain, breast, bone marrow, bone, genitourinary system, a tumor, or a wound.

US Patent:

8187608, May 29, 2012

Filed:

Sep 23, 2011

Appl. No.:

13/242783

Inventors:

Richard Gomer - Houston TX, US
Darrell Pilling - Pearland TX, US

Assignee:

William Marsh Rice University - Houston TX

International Classification:

A61K 38/00

US Classification:

4241981, 514 11, 514885

Abstract:

The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate differentiation into fibrocytes. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.

US Patent:

20050238620, Oct 27, 2005

Filed:

Jun 22, 2005

Appl. No.:

11/158966

Inventors:

Richard Gomer - Houston TX, US
Darrell Pilling - Pearland TX, US

International Classification:

A61K039/395
A61K038/48
A61K038/20
A61K038/17

US Classification:

424085200, 424094630, 424130100, 514012000

Abstract:

The present invention relates to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress the differentiation of monocytes into fibrocytes. Methods and compositions for suppressing differentiation of monocytes into fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.

US Patent:

20100297074, Nov 25, 2010

Filed:

Apr 9, 2010

Appl. No.:

12/798729

Inventors:

Richard Hans Gomer - College Station TX, US
Darrell Pilling - Pearland TX, US

International Classification:

A61K 38/20
A61K 31/729
A61K 38/18
A61P 17/02

US Classification:

424 852, 514 54, 514 91, 514 89

Abstract:

The present disclosure relates, according to some embodiments, to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-4 and IL-3 to enhance the differentiation of monocytes into fibrocytes. Methods and compositions for binding SAP, decreasing SAP levels and suppressing SAP activity are provided. Methods of using, inter alia, CPHPC, the 4,6-pyruvate acetyl of beta-D-galactopyranose, ethanolamines, high EEO agarose, IL-4, and IL-13, and anti-SAP antibodies and fragments thereof to increase monocyte differentiation into fibrocytes are provided. These methods are useful in a variety of applications, including wound healing. Wound dressings are also provided. Finally, the disclosure may include assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects.